PT  - JOURNAL ARTICLE
AU  - Jean-François Dufour
AU  - Quentin M Anstee
AU  - Elisabetta Bugianesi
AU  - Stephen Harrison
AU  - Rohit Loomba
AU  - Valerie Paradis
AU  - Herbert Tilg
AU  - Vincent Wai-Sun Wong
AU  - Shira Zelber-sagi
TI  - Current therapies and new developments in NASH
AID  - 10.1136/gutjnl-2021-326874
DP  - 2022 Jun 15
TA  - Gut
PG  - gutjnl-2021-326874
4099  - http://gut.bmj.com/content/early/2022/06/15/gutjnl-2021-326874.short
4100  - http://gut.bmj.com/content/early/2022/06/15/gutjnl-2021-326874.full
AB  - Non-alcoholic steatohepatitis is becoming the most importance etiology for advanced liver disease. The field made important progresses in the last years. The complexity of the pathophysiology of NASH is better understood. Multiple non-invasive criculating and imaging biomarkers have been tested. The importance of lifestyles has been reconised and several drugs are tested in clinical trials. This review adresses the challenges that face health care professionals in the management of NASH patients.